From discovery to clinical development, the field of protein degradation is booming with excitement, with a whole host of investments and new companies joining the effort to successfully degrade unwanted or undrugged targets with key roles in a broad range of diseases from oncology to CNS, through to autoimmune.

Despite this, key challenges remain to rapidly and successfully discover novel and underexploited Ubiquitin E3 ligases. It is now critical that we fully understand the structure and function of E3s and accelerate ligand screening with new and improved tools to make this process less lengthy and risky for biopharma.

The 3rd Annual Ligase Targeting Drug Development Summit is returning with fresh understandings and data from the forerunners of the field and those who have recently joined the space. Together we will investigate ligase structural and functional biology, screening tools for optimal ligase and ligand identification, and uncover the novel assays that are aiding validation.

This dedicated forum will provide an unrivaled meeting point for industry leaders to strategically accelerate and de-risk the process of identifying, validating, and therapeutically leveraging cell and tissue-specific Ubiquitin E3 ligases for degradation or modulation of targets of interest.

Read on go.evvnt.com

Continue reading at ligase-drugdevelopment.com

Drug Development

Facebook Share

Twitter Share

Linkedin Share

Email Share